Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-Transplant Bendamustine for GVHD Prophylaxis
NCT04022239Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine in graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2020; status: recruiting.
02
Drugs
bendamustine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04022239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022239.